Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 0.70 |
| ▸ | RAMP1 | O60894 | 7/20 | 0.70 |
| ▸ | CALCA | P06881 | 1/20 | 0.70 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.47 |
| ▸ | CALCR | P30988 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11956596 | 0.93 | CALCRL (0.71) | CALCRLRAMP1CALCARAMP3CALCR | |
| SCHEMBL11956585 | 0.93 | CALCRL (0.71) | CALCRLRAMP1CALCARAMP3CALCR | |
| SCHEMBL11956591 | 0.91 | CALCRL (0.82) | CALCRLRAMP1CALCARAMP3CALCR | |
| SCHEMBL13993515 | 0.91 | CALCRL (0.84) | CALCRLRAMP1CALCARAMP3CALCR | |
| SCHEMBL13601547 | 0.91 | CALCRL (0.84) | CALCRLRAMP1CALCARAMP3CALCR | |
| SCHEMBL11956656 | 0.90 | CALCRL (0.57) | CALCRLRAMP1CALCARAMP3CALCR | |
| SCHEMBL11956593 | 0.85 | CALCRL (0.82) | CALCRLRAMP1CALCARAMP3CALCR | |
| SCHEMBL11956651 | 0.84 | CALCRL (0.57) | CALCRLRAMP1CALCARAMP3CALCR | |
| SCHEMBL11896296 | 0.84 | CALCRL (0.83) | CALCRLRAMP1CALCARAMP3CALCR | |
| SCHEMBL11956584 | 0.84 | CALCRL (0.83) | CALCRLRAMP1CALCARAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765763-B2 | Substituted piperazines as CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-8765763-B2 | Substituted piperazines as CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-20120196872-A1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
| US-20120196872-A1 | NEW 5-ALKYNYL-PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196872-A1 | NEW 5-ALKYNYL-PYRIDINES | CALCR, CALCRL, P2RX5 | CALCRL 2/4885RAMP1 84/4885CALCA 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.